At e-SPACE CRM 2022 clinical data was analysed through a practical lens to address questions around SGLT2 inhibitor use in CKD.
Explore the data-supported discussion of the treatment landscape for patients with CKD, and other comorbidities. The inciteful conversation is led by Dr Muthiah Vaduganathan (Chair) and Professor Mustafa Arici.
This educational symposium will increase delegates' understanding of:
- SGLT2 inhibitors as part of the evidence-based CKD treatment landscape
- Data supporting the cardiorenal efficacy of SGLT2 inhibition in comorbid patients with CKD
- How clinical data from SGLT2 inhibitor trials should be applied in clinical practice
Target Audience
- Cardiologists
- Nephrologists
More from this programme
Part 1
Welcome and Introductions
| 1 session | |
| Welcome and Introductions | Watch now |
Part 2
Clinical data through a practical lens
Part 3
Discussion and Q&A
| 1 session | |
| Discussion and Q&A | Watch now |
Faculty Biographies
Mustafa Arici
Professor of Medicine (Nephrology)
Mustafa ARICI, MD., is Professor of Medicine (Nephrology) at Hacettepe University in Ankara-Turkey. He is a member of the Science Academy of Turkey, Executive Committee Member of KDIGO and Registry Committee Member of ERA-EDTA.
He undertook his undergraduate and postgraduate educations in Faculty of Medicine, Hacettepe University. He had awarded a training grant from ISN and studied in the field of “proteinuria and renal fibrosis” for two years in the Department of Nephrology, University of Leicester, UK as an ISN fellow.
His main research interests are concentrated on chronic kidney disease and hypertension with a special focus on mechanisms involved in progression of kidney disease, albuminuria and fibrosis, cardiovascular risks and complications in CKD and dialysis, epidemiology of hypertension and cardiorenal risks of sodium consumption and fluid & electrolyte disorders.
He serves as “theme editor” for “Nephrology Dialysis and…
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr. Muthiah Vaduganathan is a cardiologist and clinical trialist based in Boston, Massachusetts, United States. He practices at Brigham and Women’s Hospital and holds an academic appointment at Harvard Medical School. Dr. Vaduganathan is internationally recognised for his work at the intersection of cardiovascular, kidney, and metabolic disease, with a particular focus on translating evidence from large-scale clinical trials into routine clinical practice.
Academic History
Dr. Vaduganathan completed his medical training in the United States and pursued advanced postgraduate training in cardiovascular medicine, with a focus on heart failure and preventive cardiology. His academic development has been closely aligned with outcomes research, trial methodology, and translational science, positioning him as a leading investigator in cardio-kidney-metabolic therapeutics.
Career Overview
Dr. Vaduganathan is a Cardiologist and Clinical…